IDKmonitor^® Infliximab Free ADA ELISA Intended Use

The IDKmonitor^® Infliximab Free ADA ELISA is intended to qualitatively determine free human antibodies against Infliximab (e.g. REMICADE^®) in EDTA plasma and serum.

In combination with the drug level determination, the IDKmonitor^® Infliximab Free ADA ELISA can help physicians monitor and optimize therapy early on.

Treating Chronic Inflammatory Diseases with Anti-TNFα Antibodies

Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, or rheumatoid arthritis are often treated with anti-TNFa antibodies, which directly target the underlying inflammatory processes. The clinical efficacy of an anti-TNFa therapy correlates with the trough level of the therapeutic antibody, the drug level just before the next application of the anti-TNFa antibody. Several factors influence the trough level, among them dosage and frequency of anti-TNFa blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation anti-drug antibodies, ADA).

It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFa antibody application.

Health Canada Licensed.

Browse our other IDKmonitor^® Infliximab ELISAs.